BioAegis Therapeutics and Prenosis Collaborate on AI-Driven Precision Medicine for Inflammatory Diseases
BioAegis Therapeutics has announced a collaboration with Prenosis to evaluate biomarkers and patient subpopulations for enhanced responses to BioAegis’ gelsolin therapy targeting inflammation-related conditions such as ARDS. Their partnership aims to integrate precision medicine approaches using AI to analyze clinical data from ongoing trials, particularly those involving recombinant human plasma gelsolin.
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases